Active ingredientLarotrectinibCat. No. P-L020-001CAS 1223403-58-4Family · Pharmaceutical analytical standards
Larotrectinib
A selective TRK kinase inhibitor, approved in the United States in 2018 for adults and children with advanced solid tumours carrying an NTRK gene fusion. This family brings together the active ingredient, labelled standards, nitrosamines and other impurities.
Did you know?It was the FDA's second 'tissue-agnostic' approval: the medicine is indicated on the basis of the tumour's genetic change, not the organ where it started.
Go to the active ingredient →Active ingredientLarotrectinibCat. No. P-L020-001CAS 1223403-58-4
Active ingredientLarotrectinib SulfateCat. No. P-L020-002CAS 1223405-08-0
Isotopically labelledLarotrectinib-d4Cat. No. P-L020-003CAS 2365076-54-4
Isotopically labelledLarotrectinib-d7Cat. No. P-L020-004
NitrosamineN-Nitroso LarotrectinibCat. No. P-L020-005
Impurity5-Chloropyrazolo(1,5-a)pyrimidineCat. No. P-L020-006CAS 29274-24-6
ImpurityLarotrectinib Diastereomer ImpurityCat. No. P-L020-007CAS 2409589-59-7
ImpurityLarotrectinib Enantiomer ImpurityCat. No. P-L020-008CAS 2409590-08-3
ImpurityLarotrectinib Impurity 1 HydrochlorideCat. No. P-L020-009CAS 1443624-23-4
ImpurityLarotrectinib Impurity 2Cat. No. P-L020-010CAS 2819110-00-2
ImpurityLarotrectinib Impurity 3Cat. No. P-L020-011CAS 1223404-88-3
ImpurityLarotrectinib Impurity 4Cat. No. P-L020-012CAS 1223404-68-9No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.